The U.S. Home Infusion Therapy Market was estimated at USD 13.8 billion in 2024 and is expected to grow from USD 15.1 billion in 2025 to USD 31.4 billion by 2034, at a CAGR of 8.4%, according to the latest report published by Global Market Insights Inc.
Chronic illnesses such as cancer, diabetes, congestive heart failure, and immune deficiencies are on the rise in the U.S. Many of these conditions require long-term or recurring infusion therapies, making home infusion a more convenient and cost-effective option for patients.
Prominent players operating in the U.S. home infusion therapy industry include DAIWHA, TERUMO, MOOG, AMSINO, ICU Medical, BD, CONTEC, AVANOS, B. Braun, JMS, McKESSON, LEPU MEDICAL, Fresenius, ERENLER MEDIKAL, Baxter.
To strengthen their foothold in the U.S. home infusion therapy market, companies are deploying a mix of strategic initiatives focused on both organic growth and partnerships. Many players are expanding their service portfolios through the integration of advanced infusion devices and remote monitoring solutions that improve patient outcomes and operational efficiency. Acquisitions and mergers have also played a key role, allowing firms to broaden their geographic reach and gain access to established referral networks. Additionally, providers are investing in staff training, home care logistics, and compliance infrastructure to meet evolving regulatory standards. Customizing treatment plans and offering patient-centric care have further helped differentiate their services in a competitive market landscape.
This product will be delivered within 2-4 business days.
Chronic illnesses such as cancer, diabetes, congestive heart failure, and immune deficiencies are on the rise in the U.S. Many of these conditions require long-term or recurring infusion therapies, making home infusion a more convenient and cost-effective option for patients.
Rising Adoption of the Infusion Pumps Segment
The infusion pumps segment in the U.S. home infusion therapy market held a significant share in 2024, driven by the growing demand for controlled and precise drug delivery in home care settings. These devices offer convenience, safety, and automation, making them especially valuable for chronic conditions requiring long-term infusion, such as cancer or autoimmune diseases. With technological innovations focusing on portability, wireless monitoring, and integration with electronic health records, the infusion pump segment has seen a noticeable uptick in adoption.Increasing Demand for Anti-Infectives
The anti-infectives segment generated sustainable revenues in 2024, owing to the high incidence of infections that require intravenous antibiotic treatment. This segment includes a range of therapies targeting bacterial, fungal, and viral infections, often administered to patients recovering from surgery or managing complex infections like osteomyelitis and sepsis. The convenience of receiving anti-infective therapy at home not only reduces hospital stays but also improves patient compliance.South Atlantic to Emerge as a Lucrative Region
South Atlantic home infusion therapy market held a substantial share in 2024, fueled by a large aging population, a high prevalence of chronic diseases, and a well-established healthcare infrastructure that supports home-based services. Increasing awareness about the benefits of home infusion, along with favorable insurance coverage in this region, has further propelled market adoption.Prominent players operating in the U.S. home infusion therapy industry include DAIWHA, TERUMO, MOOG, AMSINO, ICU Medical, BD, CONTEC, AVANOS, B. Braun, JMS, McKESSON, LEPU MEDICAL, Fresenius, ERENLER MEDIKAL, Baxter.
To strengthen their foothold in the U.S. home infusion therapy market, companies are deploying a mix of strategic initiatives focused on both organic growth and partnerships. Many players are expanding their service portfolios through the integration of advanced infusion devices and remote monitoring solutions that improve patient outcomes and operational efficiency. Acquisitions and mergers have also played a key role, allowing firms to broaden their geographic reach and gain access to established referral networks. Additionally, providers are investing in staff training, home care logistics, and compliance infrastructure to meet evolving regulatory standards. Customizing treatment plans and offering patient-centric care have further helped differentiate their services in a competitive market landscape.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Zone, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The key companies profiled in this U.S. Home Infusion Therapy market report include:- B. Braun
- Baxter
- BD
- Fresenius
- ICU Medical
- LEPU MEDICAL
- McKESSON
- MOOG
- TERUMO
- AMSINO
- AVANOS
- CONTEC
- DAIWHA
- ERENLER MEDIKAL
- JMS
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 13.8 Billion |
| Forecasted Market Value ( USD | $ 31.4 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | United States |
| No. of Companies Mentioned | 16 |
